Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Smolen

Showing results (61-70 of 863) with videos related to

Pageof 87
Sort By:
Nature Reviews. Drug Discovery|March 2, 2012
Inflammatory bone loss: pathogenesis and therapeutic interventionKurt Redlich, Josef S Smolen
The Journal of Rheumatology|August 16, 2002
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational studyDaniel Aletaha, Josef S Smolen
Nature Clinical Practice. Rheumatology|August 26, 2006
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?Josef S Smolen, Daniel Aletaha
Arthritis Research & Therapy|June 1, 2011
Infliximab: 12 years of experienceJosef S Smolen, Paul Emery
Autoimmunity Reviews|May 31, 2011
Therapeutic blockade of TNF in patients with SLE-promising or crazy?Martin Aringer, Josef S Smolen
Arthritis and Rheumatism|January 5, 2011
Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactantsJosef S Smolen, Daniel Aletaha
Best Practice & Research. Clinical Rheumatology|January 24, 2012
Diseases of the musculosketelal system. PrefaceDick Heinegård, Josef S Smolen
Arthritis and Rheumatism|December 31, 2005
The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by BoersDaniel Aletaha, Josef S Smolen
Lupus|March 1, 2005
Cytokine expression in lupus kidneysM Aringer, J S Smolen
Annals of the Rheumatic Diseases|February 14, 2004
Patients with rheumatoid arthritis in clinical careJ S Smolen, D Aletaha
Pageof 87

Showing results (61-70 of 863) with videos related to

Sort By:
Pageof 87
Nature Reviews. Drug Discovery|March 2, 2012
Inflammatory bone loss: pathogenesis and therapeutic interventionKurt Redlich, Josef S Smolen
The Journal of Rheumatology|August 16, 2002
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational studyDaniel Aletaha, Josef S Smolen
Nature Clinical Practice. Rheumatology|August 26, 2006
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?Josef S Smolen, Daniel Aletaha
Arthritis Research & Therapy|June 1, 2011
Infliximab: 12 years of experienceJosef S Smolen, Paul Emery
Autoimmunity Reviews|May 31, 2011
Therapeutic blockade of TNF in patients with SLE-promising or crazy?Martin Aringer, Josef S Smolen
Arthritis and Rheumatism|January 5, 2011
Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactantsJosef S Smolen, Daniel Aletaha
Best Practice & Research. Clinical Rheumatology|January 24, 2012
Diseases of the musculosketelal system. PrefaceDick Heinegård, Josef S Smolen
Arthritis and Rheumatism|December 31, 2005
The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by BoersDaniel Aletaha, Josef S Smolen
Lupus|March 1, 2005
Cytokine expression in lupus kidneysM Aringer, J S Smolen
Annals of the Rheumatic Diseases|February 14, 2004
Patients with rheumatoid arthritis in clinical careJ S Smolen, D Aletaha
Pageof 87